About oric pharmaceuticals - ORIC
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
ORIC At a Glance
Oric Pharmaceuticals, Inc.
240 East Grand Avenue
South San Francisco, California 94080
| Phone | 1-650-388-5600 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -127,847,000.00 | |
| Sector | Health Technology | Employees | 115 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ORIC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.357 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.229 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.03 |
ORIC Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,111,713.043 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ORIC Liquidity
| Current Ratio | 10.555 |
| Quick Ratio | 10.555 |
| Cash Ratio | 10.302 |
ORIC Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -48.116 |
| Return on Equity | -54.728 |
| Return on Total Capital | -50.637 |
| Return on Invested Capital | -53.176 |
ORIC Capital Structure
| Total Debt to Total Equity | 3.849 |
| Total Debt to Total Capital | 3.706 |
| Total Debt to Total Assets | 3.381 |
| Long-Term Debt to Equity | 2.539 |
| Long-Term Debt to Total Capital | 2.445 |